Mylan
Sign in to saveAlso known as Mylan N.V., Mylan Inc., Mylan (United States)
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
OverviewAI-generated
Mylan was a company and funder established in 1961 in Canonsburg, United States. It was also known as UDL Laboratories, Inc. The organization was recognized in the Sp 500 collection.
At the time of its dissolution, Mylan employed 35,000 people. The entity was dissolved, abolished, or demolished in 2020. Its status is now inactive.
Synthesized by Vinony from 16 facts across 4 sources: Wikidata, Firecrawl, ROR, Vinony collections. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Company.name
- Mylan N.V.
- Company.logo
- Mylan Logo.svg
- Company.logo_size
- 250px
- Company.trade_name
- Mylan N.V.
- Company.former_name
- Milan
- Company.type
- Public
- Company.industry
- Pharmaceuticals
- Company.founded
- in White Sulphur Springs, West Virginia, United States
- Company.founders
- Milan PuskarDon Panoz
- Company.fate
- Merged with Upjohn to form Viatris
- Company.successor
- Viatris
- Company.hq_location_city
- Hatfield, Hertfordshire
- Company.hq_location_country
- United Kingdom
- Company.products
- Generic and specialty pharmaceuticals and active pharmaceutical ingredients
- Company.divisions
- see Operations
via Wikipedia infobox
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1961
- Location
- Canonsburg, United States
- Also known as
- UDL Laboratories, Inc.
- Status
- Inactive
GRID grid.476548.c
Official website
Mylan - Now a Part of Viatris
mylan.com →Link to the official site · 424 chars · not written by Vinony
Wikidata facts
- Instance of
- public company
- Part of
- S&P 500
- Official name
- Mylan N.V.
- Country
- Netherlands
- Founded by
- Don Panoz
- Headquarters
- Canonsburg
- Parent organization
- Viatris
- Industry
- health care industry
- Employees
- 35000
- Stock exchange
- Tel Aviv Stock Exchange
- Legal form
- naamloze vennootschap
- Official website
- www.mylan.com
Show 9 more facts
- inception
- 1961-01-01
- Commons category
- Mylan
- location of formation
- White Sulphur Springs
- native label
- Mylan
- market capitalization
- 21200000000
- dissolved, abolished or demolished date
- 2020-11-00
- social media followers
- 11192
- replaced by
- Viatris
- different from
- Upjohn
Sources (7)
via Wikidata · CC0
~28 min read
Encyclopedic overview
36 sectionsContents
- Corporate headquarters
- Stock
- History
- Founding to 1980
- 1980s
- Dyazide & Maxzide
- Acquisitions begin
- 1990s
- 2000s
- Attempted King Pharmaceuticals acquisition
- Matrix acquisition
- EpiPen acquisition
- 2010s
- Generic Advair agreement
- EpiPen4Schools launch
- Agila acquisition
- Abbott acquisition
- Attempted Perrigo acquisition
- Attempted purchase by Teva
- New COPD drug
- Meda acquisition
- Valsartan recall
- Generic Advair approval
- Merger with Pfizer's off-patent drug business and name change to Viatris
- Stock
- Acquisition history
- Criticism
- EpiPen pricing
- Executive pay
- Execution drugs
- Products
- Generic Medicines
- Branded Medicines
- Management
- References
- External links
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and specialty pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.
Excerpted from Wikipedia’s “Mylan” article, available under the CC BY-SA 4.0 licence.